Proportion increases when considering off-label use but drops when considering drugs with substantial clinical benefit.

We think it can be appropriate to present phase 2 trial participation as offering a small prospect of benefit,” researchers wrote. About 16% of patients enrolled in phase 2 cancer trials receive a ...

About ALLEVIATE-1 The ALLEVIATE-1 clinical trial (NCT06545097) is a Phase 3 multicenter, randomized, double-blind, placebo-controlled study. The primary objective of ALLEVIATE-1 is to evaluate the ...